Showing 5481-5490 of 6661 results for "".
- In Review: VCS Virtual Format Hailed as a Successhttps://practicaldermatology.com/news/in-review-vcs-virtual-format-hailed-a-success/2460601/After a decade and a half of bringing topline aesthetic education to Las Vegas, VCS went virtual this fall. “While it wasn't live—it was virtual—I knew it was absolutely fantastic,” says meeting
- Two New Studies Suggest Age Is A Primary Determinant Of Melanoma Treatment Resistancehttps://practicaldermatology.com/news/two-new-studies-suggest-age-is-a-primary-determinant-of-melanoma-treatment-resistance/2460595/Age is a primary factor in treatment response in animal and laboratory models of melanoma cells, according to two new studies. The new findings by Johns Hopkins Kimmel Cancer Center and
- New Government Advisory Cites Risk for Ransomware Attacks on Healthcare Systemhttps://practicaldermatology.com/news/new-government-advisory-cites-risk-for-ransomware-attacks-on-healthcare-system/2460587/A new advisory coauthored by the Cybersecurity and Infrastructure Security Agency (CISA), the Federal Bureau of Investigation (FBI), and the Department of Health and Human Services (HHS) warns of the potential for ransomware attacks against hospitals and medical systems. “CI
- Where is the Hydroquinone? Regulatory Change Hinders Accesshttps://practicaldermatology.com/news/where-is-the-hydroquinone-regulatory-change-hinders-access/2460586/Changes to FDA regulations implemented as part of the CARES Act this spring have left dermatologists and their patients scrambling to access hydroquinone. Although access is hindered, it is not cut off. “I think most people at this point are familiar with the CARES Act. What they
- Exclusive: Global Report Identifies Strategies for Improved Quality of Care in ADhttps://practicaldermatology.com/news/exclusive-global-report-identifies-strategies-for-improved-quality-of-care-in-ad/2460585/Gathering and synthesizing data from in-person visits from 32 care centers in 17 countries around the world, the “Improving Quality of Care in AD” report offers clear recommendations to improve care and help patients better manage atopic dermatitis.Commissioned and funded by Sano
- Sklice Goes Over-the-Counterhttps://practicaldermatology.com/news/sklice-goes-over-the-counter/2460581/Sklice (ivermectin) lotion, 0.5% is now approved for OTC sale. Sklice (Arbor Pharmaceuticals) was originally FDA approved as a prescription treatment for head lice infestation in patients six months of age and older in February 2012. “The Rx-t
- The HydraFacial Company And Circadia Expand Partner Boosters Globallyhttps://practicaldermatology.com/news/the-hydrafacial-company-and-circadia-expand-partner-boosters-globally/2460579/The HydraFacial Company is extending their partnership with Circadia to offer the Chrono-Peptide Booster and ProTec Plus Booster to HydraFacial providers in more than 40 countries. "The Circadia boosters for HydraFacial are already loved by providers and consume
- Alastin SkinCare Hits Canadahttps://practicaldermatology.com/news/alastin-skincare-hits-canada/2460568/Alastin Skincare, Inc. is now available in Caanada via partnership with AVARI Medical Ltd. "Alastin Skincare has established a leadership position in the US, achieving the fastest growth rate in the professional skincare channel for three years in a row. In addition to contin
- ADCS Acquires Montgomery Dermatology; Catawba Research Enters Partnershiphttps://practicaldermatology.com/news/adcs-acquires-montgomery-dermatology-catawba-research-enters-partnership/2460565/Advanced Dermatology and Cosmetic Surgery (ADCS), the largest dermatology practice in the US, has acquired Dermatology Associates of Montgomery, a leading dermatology practice based in the Southeast. Bundy Group served as exclusive financial advisor to Dr. Steve Maddox, owner of Dermatology
- Brickell Biotech Initiates Phase 3 Trial of Sofpironium Bromide Gel for Hyperhidrosishttps://practicaldermatology.com/news/brickell-biotech-initiates-phase-3-trial-of-sofpironium-bromide-gel-for-hyperhidrosis/2460554/Brickell Biotech, Inc. has initiated its first pivotal US Phase 3 clinical study evaluating sofpironium bromide gel, 15% as a potential treatment for primary axillary hyperhidrosis (“Cardigan I Study”). “This continues to be an exciting time for Brickell, with initiati